Publications.
Altenburg AF, Morley JL, Bauer J, Walz JW, Boyle LH (2024). Wellcome Open Research. [version 1; peer review: awaiting peer review]
Distinct Polymorphisms in HLA Class I Molecules Govern Their Susceptibility to Peptide Editing by TAPBPR.
Ilca FT, Drexhage LZ, Brewin G, Peacock S, Boyle LH (2019). Cell Rep. 29(6):1621-1632
TAPBPR bridges UDP-glucose:glycoprotein glucosyltransferase 1 onto MHC class I to provide quality control in the antigen presentation pathway.
Neerincx A, Hermann C, Antrobus R, van Hateren A, Cao H, Trautwein N, Stevanović S, Elliott T, Deane JE, Boyle LH (2017). eLife. 6:e23049.
TAPBPR mediates peptide dissociation from MHC class I using a leucine lever.
Ilca FT, Neerincx A, Hermann C, Marcu A, Stevanović S, Deane JE, Boyle LH (2018). eLife. 7:e40126
TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst.
Hermann C, van Hateren A, Trautwein N, Neerincx A, Duriez PJ, Stevanović S, Trowsdale J, Deane JE, Elliott T, Boyle LH (2015). eLife. 4:e09617.
The glycosylation status of MHC class I molecules impacts their interactions with TAPBPR.
Ilca FT, Boyle LH (2021). Molecular Immunology. Nov;139:168-176
Utilizing TAPBPR to promote exogenous peptide loading onto cell surface MHC I molecules.
Ilca FT, Neerincx A, Wills MR, de la Roche M, Boyle LH (2018). Proc Natl Acad Sci U S A. 115:E9353-E9361
Tapasin-related protein TAPBPR is an additional component of the MHC class I presentation pathway.
Boyle LH, Hermann C, Boname JM, Porter KM, Patel PA, Burr ML, Duncan LM, Harbour ME, Rhodes DA, Skjødt K, Lehner PJ, Trowsdale J (2013). Proc Natl Acad Sci U S A. 110:3465-70.